AMENDMENT

Subject matter to be added is in bold and underlined.

Subject matter to be deleted is in bold and strikethrough.

In the Claims:

Please enter rewritten claims 21-23 and new claims 32-46 as follows. Please cancel claim 31 without prejudice or disclaimer.

This listing of claims will replace all prior versions and listings of claims in the application.

1. (Previously presented) A compound according to formula (I),



(I)

or a stereoisomer or a pharmaceutically-acceptable salt thereof, wherein:

X is –OH, –O(alkyl), –O(aryl), –O(arylalkyl), $-NR_5$(aryl), or $-NR_5$(arylalkyl); wherein said aryl or arylalkyl are optionally substituted with one to two R_{25};

W is hydrogen or $-(CR_7R_8)_q$-H;

Z is isoquinolyl optionally substituted with 1-3 substituents selected from R_9 and/or R_{10};

R_1, R_2 and R_3 are attached to any available carbon atom of phenyl ring A and are independently selected from hydrogen, halogen, cyano, nitro, C_{1-10}alkyl, C_{2-10}alkenyl, substituted C_{1-10}alkyl, substituted C_{2-10}alkenyl, $-C(=O)NR_{12}R_{13}$, $-OR_{12}$, $-CO_2R_{12}$, $-C(=O)R_{12}$, $-SR_{12}$, $-S(O)_tR_{15}$, $-NR_{12}R_{13}$, $-NR_{12}SO_2R_{15}$, $-NR_{14}SO_2NR_{12}R_{13}$,

$-NR_{12}CO_2R_{13}$, $-NR_{12}C(=O)R_{13}$, $-NR_{14}C(=O)NR_{12}R_{13}$, $-SO_2NR_{12}R_{13}$, aryl, heteroaryl, cycloalkyl, and heterocyclo;

R_5 is hydrogen, C_{1-4}alkyl, NH_2, C_{1-4}alkylamino, hydroxy, or C_{1-4}alkoxy;

R_7 and R_8 are independently selected from hydrogen, $-OR_{18}$, $-NR_{18}R_{19}$, $-NR_{18}SO_2R_{20}$, alkyl, alkenyl, substituted alkyl, substituted alkenyl, halogen, haloalkyl, haloalkoxy, cyano, nitro, alkylthio, $-C(=O)H$, acyl, $-CO_2H$, alkoxycarbonyl, sulfonamido, sulfonyl, and phenyl in turn optionally substituted with 1-3 of halogen, cyano, haloalkyl, haloalkoxy, nitro, hydroxy, C_{1-4}alkyl, C_{1-4}hydroxyalkyl, C_{1-4}alkoxy, amino, $NH(C_{1-4}alkyl)$, $N(C_{1-4}alkyl)_2$, and/or C_{1-4}aminoalkyl;

R_9 and R_{10} are independently selected from hydrogen, halogen, alkyl, substituted alkyl, haloalkyl, haloalkoxy, cyano, nitro, $-S(O)_uR_{21}$, $-NR_{22}SO_2R_{21}$, $-C(=O)NR_{22}R_{23}$, $-OR_{22}$, $-CO_2R_{22}$, $-C(=O)R_{22}$, $-SR_{22}$, $-NR_{22}R_{23}$, $-NR_{22}CO_2R_{23}$, $-NR_{22}C(=O)R_{23}$, $-NR_{22}C(=O)NR_{23}R_{24}$, $-SO_2NR_{22}R_{23}$, $-NR_{22}SO_2NR_{23}R_{24}$, $-C(=NR_{22})NR_{23}R_{24}$, five or six membered heterocyclo or heteroaryl, phenyl, and C_{3-7}cycloalkyl; wherein when R_9 or R_{10} is selected from heterocyclo, heteroaryl, phenyl, and C_{3-7}cycloalkyl, each of said cyclic groups in turn is optionally substituted with up to three of C_{1-4}alkyl, C_{1-4}alkoxy, C_{1-4} hydroxyalkyl, C_{1-4} aminoalkyl, halogen, hydroxy, haloalkyl, haloalkoxy, amino, C_{1-4} alkylamino, and/or cyano;

R_{12}, R_{13}, R_{14}, R_{18}, R_{19}, R_{22} R_{23}, and R_{24} are independently selected from hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, aryl, heteroaryl, cycloalkyl, and heterocyclo;

R_{15}, R_{20} and R_{21} are independently selected from alkyl, substituted alkyl, alkenyl, substituted alkenyl, aryl, heteroaryl, cycloalkyl, and heterocyclo;

R_{25} at each occurrence is selected from hydrogen, halogen, cyano, nitro, C_{1-10}alkyl, C_{2-10}alkenyl, substituted C_{1-10}alkyl, substituted C_{2-10}alkenyl, $-C(=O)NR_{12}R_{13}$, $-OR_{12}$, $-CO_2R_{12}$, $-C(=O)R_{12}$, $-SR_{12}$, $-S(O)_tR_{15}$, $-NR_{12}R_{13}$, $-NR_{12}SO_2R_{15}$, $-NR_{14}SO_2NR_{12}R_{13}$, $-NR_{12}CO_2R_{13}$, $-NR_{12}C(=O)R_{13}$, $-NR_{14}C(=O)NR_{12}R_{13}$, $-SO_2NR_{12}R_{13}$, aryl, heteroaryl, cycloalkyl, and heterocyclo;

p is 1 or 2;

q is 1, 2 or 3;

t is 1 or 2; and

u is 1 or 2.

2. (Previously presented) A compound according to claim 1, or a stereoisomer or a pharmaceutically-acceptable salt thereof, wherein the compound is of formula (Ia):



(Ia),

X is –OH, –O(phenyl) optionally substituted with one to two R_{25}, –O(benzyl) optionally substituted with one to two R_{25}, –NH(phenyl) optionally substituted with one to two R_{25}, or –NH(benzyl) optionally substituted with one to two R_{25};

W is hydrogen or $-(CH_2)_q$-H;

Z is isoquinolyl optionally substituted with 1-3 substituents selected from R_9 and/or R_{10};

R_1 and R_2 are independently selected from hydrogen, halogen, cyano, nitro, C_{1-10}alkyl, C_{2-10}alkenyl, substituted C_{1-10}alkyl, substituted C_{2-10}alkenyl, $-C(=O)NR_{12}R_{13}$, $-OR_{12}$, $-CO_2R_{12}$, $-C(=O)R_{12}$, $-SR_{12}$, $-S(O)_tR_{15}$, $-NR_{12}R_{13}$, $-NR_{12}SO_2R_{15}$, $-NR_{14}SO_2NR_{12}R_{13}$, $-NR_{12}CO_2R_{13}$, $-NR_{12}C(=O)R_{13}$, $-NR_{14}C(=O)NR_{12}R_{13}$, $-SO_2NR_{12}R_{13}$, aryl, heteroaryl, cycloalkyl, and heterocyclo;

R_9 and R_{10} are independently selected from hydrogen, halogen, alkyl, substituted alkyl, haloalkyl, haloalkoxy, cyano, nitro, $-S(O)_uR_{21}$, $-NR_{22}SO_2R_{21}$, $-C(=O)NR_{22}R_{23}$, $-OR_{22}$, $-CO_2R_{22}$, $-C(=O)R_{22}$, $-SR_{22}$, $-NR_{22}R_{23}$, $-NR_{22}CO_2R_{23}$, $-NR_{22}C(=O)R_{23}$,

$-NR_{22}C(=O)NR_{23}R_{24}$, $-SO_2NR_{22}R_{23}$, $-NR_{22}SO_2NR_{23}R_{24}$, $-C(=NR_{22})NR_{23}R_{24}$, five or six membered heterocyclo or heteroaryl, phenyl, and C_{3-7}cycloalkyl; wherein when R_9 or R_{10} is selected from heterocyclo, heteroaryl, phenyl, and C_{3-7}cycloalkyl, each of said cyclic groups in turn is optionally substituted with up to three of C_{1-4}alkyl, C_{1-4}alkoxy, C_{1-4} hydroxyalkyl, C_{1-4} aminoalkyl, halogen, hydroxy, haloalkyl, haloalkoxy, amino, C_{1-4} alkylamino, and/or cyano;

R_{12}, R_{13}, R_{14}, R_{18}, R_{19}, R_{22} R_{23}, and R_{24} are independently selected from hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, aryl, heteroaryl, cycloalkyl, and heterocyclo;

R_{15}, R_{20} and R_{21} are independently selected from alkyl, substituted alkyl, alkenyl, substituted alkenyl, aryl, heteroaryl, cycloalkyl, and heterocyclo;R_{16} is alkyl, substituted alkyl, alkenyl, substituted alkenyl, aryl, heteroaryl, cycloalkyl, or heterocyclo;

p is 1 or 2;

q is 1, 2 or 3; and

u is 1 or 2.

3. (Previously presented) A compound according to claim 2, wherein:

X is selected from –OH, –O(phenyl), –O(benzyl), –NH(phenyl), and wherein each phenyl or benzyl group is optionally subsituted with one to two R_{25},

W is hydrogen or $-(CH_2)_q$-H;

Z is 

;

R_1 and R_2 are OR_{12};

R_9 is selected from hydrogen, halogen, alkyl, substituted alkyl, haloalkyl, haloalkoxy, cyano, nitro, $-S(O)_uR_{21}$, $-NR_{22}SO_2R_{21}$, $-C(=O)NR_{22}R_{23}$, $-OR_{22}$, $-CO_2R_{22}$, $-C(=O)R_{22}$, $-SR_{22}$, $-NR_{22}R_{23}$, $-NR_{22}CO_2R_{23}$, $-NR_{22}C(=O)R_{23}$, $-NR_{22}C(=O)NR_{23}R_{24}$,

$-SO_2NR_{22}R_{23}$, $-NR_{22}SO_2NR_{23}R_{24}$, five or six membered heterocyclo or heteroaryl, phenyl, and C_{3-7}cycloalkyl;

R_{12}, R_{22}, R_{23} and R_{24} are selected from hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, aryl, heteroaryl, cycloalkyl, or heterocyclo;

R_{21} is selected from alkyl, substituted alkyl, alkenyl, substituted alkenyl, aryl, heteroaryl, cycloalkyl, and heterocyclo;

R_{25} at each occurrence is selected from C_{1-4}alkyl, C_{1-4}alkoxy, C_{1-4}hydroxyalkyl, C_{1-4}aminoalkyl, halogen, hydroxy, haloalkyl, haloalkoxy, amino, C_{1-4}alkylamino, and/or cyano;

q is 1, 2 or 3;

s is 0, 1, or 2; and

u is 1 or 2.

4. (Previously presented) A compound according to claim 1, or a stereoisomer or a pharmaceutically-acceptable salt thereof, wherein the compound is of formula (Ib),



(Ib),

wherein:

X is selected from –O(phenyl), –O(benzyl), and –NH(phenyl) –NH(benzyl), wherein each group X is optionally subsituted with one to two R_{25},

W is hydrogen or $-(CH_2)_q$-H;

Z is  ;

R_9 is independently selected from hydrogen, halogen, alkyl, aminoalkyl, hydroxyalkyl, haloalkyl, haloalkoxy, alkoxy, cyano, nitro, alkylamino, alkylthio, thioalkyl, -C(=O)NH_2, –C(=O)NH(C_{1-4}alkyl), –C(=O)N(C_{1-4}alkyl)$_2$, five or six membered heterocyclo or heteroaryl, phenyl, and C_{3-7}cycloalkyl;

R_{12a} and R_{12b} are independently selected from hydrogen, alkyl, substituted alkyl, phenyl, and benzyl;

R_{25} at each occurrence is selected from C_{1-4}alkyl, C_{1-4}alkoxy, C_{1-4}hydroxyalkyl, C_{1-4}aminoalkyl, halogen, hydroxy, haloalkyl, haloalkoxy, amino, C_{1-4}alkylamino, and/or cyano;

p is 1 or 2; and

s is 0, 1 or 2.

5. (Previously presented) A compound according to claim 1, or a stereoisomer or a pharmaceutically-acceptable salt thereof, wherein Z is selected from:

 and  ;

Z_6 is fused to ring A comprising the common carbon atom C* and is

 ;

Z_7 is fused to ring A comprising the common carbon atom C* and is selected from:

 and  ;

r is 0, 1, or 2; and

s is 0, 1, 2, or 3.

6. (Previously presented) A compound according to claim 1, or a stereoisomer or a pharmaceutically-acceptable salt thereof, wherein Z is selected from:



7. (Previously presented) A compound according to claim 1, or a stereoisomer or a pharmaceutically-acceptable salt thereof, wherein R_1 and R_2 are OR_{12}.

8. (Previously presented) A compound according to claim 7, or a stereoisomer or a pharmaceutically acceptable salt thereof, wherein R_{12} is $C_{1\text{-}6}$alkyl, phenyl, or benzyl optionally substituted with one to two of halogen, cyano, haloalkyl, haloalkoxy, nitro, hydroxy, $C_{1\text{-}4}$alkyl, $C_{1\text{-}4}$hydroxyalkyl, $C_{1\text{-}4}$alkoxy, amino, $NH(C_{1\text{-}4}alkyl)$, and $N(C_{1\text{-}4}alkyl)_2$.

9. (Previously presented) A compound according to claim 8, or a stereoisomer or a pharmaceutically-acceptable salt thereof, wherein W is hydrogen.

10. (Previously presented) A compound according to claim 9, or a stereoisomer or a pharmaceutically-acceptable salt thereof, wherein X is NH(phenyl), or NH(benzyl).

11. (Previously presented) A compound having the formula (Ib),



(Ib)

or a stereoisomer or a pharmaceutically-acceptable salt thereof, wherein:

X is selected from –O(phenyl) optionally substituted with one to two R_{25}, –O(benzyl) optionally substituted with one to two R_{25}, –NH(phenyl) optionally substituted with one to two R_{25}, and –NH(phenylalkyl) optionally substituted with one to two R_{25};

W is hydrogen or $-(CH_2)_q$-H;

Z is selected from:



;

Z_6 is fused to ring A comprising the common carbon atom C* and is



;

Z_7 is fused to ring A comprising the common carbon atom C* and is selected from:



;

R_9 is independently selected from hydrogen, halogen, alkyl, substituted alkyl, haloalkyl, haloalkoxy, cyano, nitro, $-S(O)_uR_{21}$, $-NR_{22}SO_2R_{21}$, $-C(=O)NR_{22}R_{23}$, $-OR_{22}$, $-CO_2R_{22}$, $-C(=O)R_{22}$, $-SR_{22}$, $-NR_{22}R_{23}$, , $-NR_{22}CO_2R_{23}$, $-NR_{22}C(=O)R_{23}$,

$-NR_{22}C(=O)NR_{23}R_{24}$, $-SO_2NR_{22}R_{23}$, - $NR_{22}SO_2NR_{23}R_{24}$, $-C(=NR_{22})NR_{23}R_{24}$, five or six membered heterocyclo or heteroaryl, phenyl, and C_{3-7}cycloalkyl, provided that R_9 is not $-C(=NR_{22})NR_{23}R_{24}$ when W is hydrogen; wherein when R_9 is independently selected from heterocyclo, heteroaryl, phenyl, and C_{3-7}cycloalkyl, each of said cyclic groups in turn is optionally substituted with up to three of C_{1-4}alkyl, C_{1-4}alkoxy, C_{1-4}hydroxyalkyl, C_{1-4}aminoalkyl, halogen, hydroxy, haloalkyl, haloalkoxy, amino, C_{1-4}alkylamino, and/or cyano;

R_{12}, R_{12a}, R_{12b}, R_{22} R_{23}, and R_{24} are independently selected from hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, aryl, heteroaryl, cycloalkyl, and heterocyclo;

R_{21} is selected from alkyl, substituted alkyl, alkenyl, substituted alkenyl, aryl, heteroaryl, cycloalkyl, and heterocyclo;

R_{25} at each occurrence is selected from C_{1-4}alkyl, C_{1-4}alkoxy, C_{1-4}hydroxyalkyl, C_{1-4}aminoalkyl, halogen, hydroxy, haloalkyl, haloalkoxy, amino, C_{1-4}alkylamino, and/or cyano;

p is 1 or 2;

q is 1, 2 or 3;

r is 0, 1, or 2;

s is 0, 1, 2, or 3;

t is 1 or 2; and

u is 1 or 2.

12. (Previously presented) A compound according to claim 11, or a stereoisomer or a pharmaceutically-acceptable salt thereof, wherein Z is 

.

13. (Original) A compound according to claim 1, wherein:

X is NR_5(benzyl) optionally substituted with one to two R_{25};

W is hydrogen;

Z is  ; and

R_{25} at each occurrence is selected from halogen, cyano, nitro, C_{1-10}alkyl, C_{2-10}alkenyl, substituted C_{1-10}alkyl, substituted C_{2-10}alkenyl, $-C(=O)NR_{12}R_{13}$, $-OR_{12}$, $-CO_2R_{12}$, $-C(=O)R_{12}$, $-SR_{12}$, $-S(O)_tR_{15}$, $-NR_{12}R_{13}$, $-NR_{12}SO_2R_{15}$, $-NR_{14}SO_2NR_{12}R_{13}$, $-NR_{12}CO_2R_{13}$, $-NR_{12}C(=O)R_{13}$, $-NR_{14}C(=O)NR_{12}R_{13}$, $-SO_2NR_{12}R_{13}$, aryl, heteroaryl, cycloalkyl, and heterocyclo.

14. (Original) A compound according to claim 13, wherein:

Z is  .

15. (Original) A compound according to claim 13, wherein:

Z is  .

16. (Original) A compound according to claim 1, wherein:

X is OH;

W is hydrogen; and

Z is 

17. (Original) A compound according to claim 16, wherein:

Z is 

18. (Original) A compound according to claim 16, wherein:

Z is 

19. (Previously presented) A compound according to claim 1, wherein the compound is selected from the group:

(1-Amino-isoquinolin-6-ylamino)-(3-ethoxy-4-isopropoxy-phenyl)-acetic acid; and

2-(1-Amino-isoquinolin-6-ylamino)-N-benzyl-2-(3-ethoxy-4-isopropoxy-phenyl)-acetamide; or a stereoisomer or a pharmaceutically-acceptable salt thereof.

20. (Original) A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of Claim 1, or a stereoisomer or a pharmaceutically-acceptable salt thereof.

21. (Currently amended) A method for treating a **thrombosis** ~~**a thromboembolic disorder**~~, comprising: administering to a patient in need thereof a therapeutically effective amount of a compound of Claim 1, or a stereoisomer or a pharmaceutically acceptable salt thereof.

22. (Currently amended) A method ~~**according to Claim 21,**~~ **for treating a cardiovascular disease associated with the activation of the coagulation cascade in thrombotic or thrombophilic states** ~~**wherein the thromboembolic disorder is selected from the group consisting of arterial cardiovascular thromboembolic disorders, venous cardiovascular thromboembolic disorders, and thromboembolic disorders in the chambers of the heart**~~ **comprising: administering to a patient in need thereof a therapeutically effective amount of a compound of Claim 1 or a pharmaceutically acceptable salt, or hydrate thereof**.

23. (Currently amended) A method according to Claim ~~**21**~~ **22**, wherein the **cardiovascular disease is selected from arterial thrombosis, coronary artery disease, acute coronary syndromes, myocardial infarction, unstable angina, chronic stable angina, Prinzmetal's angina, ischemia resulting from vascular occlusion cerebral infarction, stroke, cerebral vascular diseases including cerebrovascular accident and transient ischemic attack, atherosclerotic plaques, transplant atherosclerosis, peripheral arterial disease, intermittent claudication, and embolisms** ~~**thromboembolic disorder is selected from unstable angina, an acute coronary syndrome, first myocardial infarction, recurrent myocardial infarction, ischemic sudden death, transient ischemic attack, stroke, atherosclerosis, peripheral occlusive arterial disease, venous thrombosis, deep vein thrombosis, thrombophlebitis, arterial embolism, coronary arterial thrombosis, cerebral arterial thrombosis, cerebral embolism, kidney embolism, pulmonary embolism, and thrombosis resulting from (a) prosthetic valves or other implants, (b) indwelling catheters, (c) stents, (d) cardiopulmonary bypass, (e) hemodialysis, or (f) other procedures in which blood is exposed to an artificial surface that promotes thrombosis**~~.

24-27. (Canceled)

28. (Previously presented) A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of Claim 2, or a stereoisomer or a pharmaceutically-acceptable salt thereof.

29. (Previously presented) A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of Claim 3, or a stereoisomer or a pharmaceutically-acceptable salt thereof.

30. (Previously presented) A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of Claim 4, or a stereoisomer or a pharmaceutically-acceptable salt thereof.

31. Canceled.

32. (New) A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of Claim 5, or a stereoisomer or a pharmaceutically-acceptable salt thereof.

33. (New) A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of Claim 6, or a stereoisomer or a pharmaceutically-acceptable salt thereof.

34. (New) A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of Claim 7, or a stereoisomer or a pharmaceutically-acceptable salt thereof.

35. (New) A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of Claim 8, or a stereoisomer or a pharmaceutically-acceptable salt thereof.

36. (New) A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of Claim 9, or a stereoisomer or a pharmaceutically-acceptable salt thereof.

37. (New) A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of Claim 10, or a stereoisomer or a pharmaceutically-acceptable salt thereof.

38. (New) A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of Claim 11, or a stereoisomer or a pharmaceutically-acceptable salt thereof.

39. (New) A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of Claim 12, or a stereoisomer or a pharmaceutically-acceptable salt thereof.

40. (New) A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of Claim 13, or a stereoisomer or a pharmaceutically-acceptable salt thereof.

41. (New) A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of Claim 14, or a stereoisomer or a pharmaceutically-acceptable salt thereof.

42. (New) A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of Claim 15, or a stereoisomer or a pharmaceutically-acceptable salt thereof.

43. (New) A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of Claim 16, or a stereoisomer or a pharmaceutically-acceptable salt thereof.

44. (New) A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of Claim 17, or a stereoisomer or a pharmaceutically-acceptable salt thereof.

45. (New) A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of Claim 18, or a stereoisomer or a pharmaceutically-acceptable salt thereof.

46. (New) A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of Claim 19, or a stereoisomer or a pharmaceutically-acceptable salt thereof.